Unique molecule life cycle platform released: Torx® 2.0

Cambridge, UK – June 13th 2023 – Torx ® Software Limited, announces the release of Torx 2.0, extending the platform’s scientific reach and capabilities to deliver unrivalled seamless integration across the drug discovery Design-Make-Test-Analyze (DMTA) cycle.

Torx is a visual, chemistry aware, cloud-native platform. By enabling chemistry teams to design molecules, track compound synthesis from start to finish and gain insightful analysis, Torx inspires discovery chemistry teams to work together and deliver faster. Benefits and features Torx 2.0 delivers include:

• New holistic view of all Test requests across Biology, Physicochemical and ADME departments that enables both visualization of existing and scheduling of new tests for individual, sets or all project compounds.
• Improved user interface for viewing and communicating CRO workload in synthetic chemistry.
• Covalent docking enabling a wider range of projects to benefit from the integrated 3D pose generation.
• Integration with CAS SciFinder, offering easy interrogation of synthetic feasibility, reagent availability and any patentability issues.
• Live merging of data from multiple corporate repositories with existing molecule design data, giving medicinal chemists the complete picture for decision making and progressing to the next DMTA cycle.

Dr. Tim Cheeseright, CEO, Torx Software, commented: “Research chemists have the complex role of juggling multiple projects across different stages of the drug discovery cycle simultaneously. Working with disparate teams or partnering with external organizations and CROs adds further complexity and can lead to productivity bottlenecks and slow the whole team down."

Tim Cheeseright continued: “Torx is an unrivalled DMTA solution for managing the complete molecule life-cycle in a single platform, from ideation to synthesis, testing and data analysis. By integrating Torx into their drug discovery programs, research chemists can work collaboratively to design, review, prioritize and schedule all parts of the complex drug design process; and research managers are able to better plan, manage and track their DMTA workflows across all R&D projects.”

Dr. Toni Kline, Senior Director of Chemistry at Engine Biosciences, commented: "Torx is a powerful tool for organizing our molecule design library, especially as our group grows in size. By providing immediate, real-time access to design and synthesis information, Torx ensures that we are investing our resources in the most critical compounds.”

Media Contacts

●        Andrew Hair, PR Manager,      ramarketing, andrew.hair@ramarketingpr.com, +44 0191 222 1242

●        Sue Peffer, Head of Marketing, news@torx-software.com

About Torx Software

Torx software is the synergistic collaboration between Cresset and Elixir Software, producing the only complete DMTA (design-make-test-analyze) solution on the market. Its visual web-based platform enables medicinal/synthetic chemists and research teams to coordinate efforts and optimize the entire molecule design, compound synthesis, testing and data analysis cycle. For more information visit www.torx-software.com